Understanding innate resistance to anti-PD1 in melanoma with Ingenuity Pathway Analysis (IPA) and OmicSoft


Join us for a webinar to explore innate resistance to anti-PD1 in melanoma using solutions from Ingenuity Pathway Analysis and OmicSoft. Using transcriptomics, we will describe the following:
 
• Analyzing non-responder versus responder gene expression signatures to pinpoint significant genes and pathways associated with advanced melanoma.
• Identifying significantly differential expression of isoforms and their association with advanced melanoma.
• Generating novel regulatory networks as drivers of the expression changes observed in the innate anti-PD1 resistance treatment in advanced melanoma.
• Comparing this analysis across a repository of processed datasets from OmicSoft Lands.
• Visualizing a specific gene of interest in OncoLand.

Jean-Noel Billaud

Jean Noel Billaud
Jean-Noël Billaud, Ph.D. is Senior Principal Scientist at QIAGEN Bioinformatics. Before joining QIAGEN Bioinformatics, Dr. Billaud joined Ingenuity Systems 2008 as a staff scientist for in silico research program in oncology and infectious diseases. Jean-Noël Billaud holds a Ph.D. in Blood Cell Biology from Paris VII, and completed his post-doctoral work at the Scripps Research Institute (San Diego, CA) studying the impact of Feline Immunodeficiency Virus and Borna Disease Virus on brain cells. He pursued his career at the Vaccine Research Institute of San Diego where he co-developed a universal vaccine platform using the core antigen of Hepatitis B Virus in order to target infectious (viral and parasitic) diseases as well as metabolic diseases and cancer.